Protagonist Therapeutics (PTGX) Projected to Post Quarterly Earnings on Wednesday

Protagonist Therapeutics (NASDAQ:PTGX) will likely be issuing its Q4 2025 results before the market opens on Wednesday, March 18th. Analysts expect Protagonist Therapeutics to post earnings of ($0.5415) per share and revenue of $14.9160 million for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Wednesday, February 25, 2026 at 12:30 PM ET.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its quarterly earnings data on Wednesday, February 25th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.16). Protagonist Therapeutics had a negative net margin of 282.83% and a negative return on equity of 19.89%. The business had revenue of $7.44 million during the quarter, compared to analyst estimates of $14.92 million. On average, analysts expect Protagonist Therapeutics to post $2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Protagonist Therapeutics Trading Up 0.4%

Shares of PTGX opened at $97.05 on Wednesday. The stock has a market capitalization of $6.19 billion, a price-to-earnings ratio of -47.34 and a beta of 2.23. Protagonist Therapeutics has a 12 month low of $39.60 and a 12 month high of $98.21. The firm has a fifty day simple moving average of $85.07 and a 200 day simple moving average of $79.02.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Citizens Jmp increased their price objective on shares of Protagonist Therapeutics from $102.00 to $112.00 and gave the stock a “market outperform” rating in a research note on Thursday, February 26th. HC Wainwright lifted their target price on Protagonist Therapeutics from $80.00 to $117.00 and gave the company a “buy” rating in a research report on Friday, January 30th. Citigroup upped their target price on Protagonist Therapeutics from $98.00 to $115.00 and gave the stock a “buy” rating in a report on Monday, December 8th. Truist Financial increased their price target on Protagonist Therapeutics from $88.00 to $110.00 and gave the company a “buy” rating in a research report on Monday, January 5th. Finally, TD Cowen raised their price target on Protagonist Therapeutics from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $101.08.

Insiders Place Their Bets

In other news, Director Lewis T. Williams sold 18,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $82.42, for a total value of $1,483,560.00. Following the completion of the sale, the director directly owned 7,825 shares of the company’s stock, valued at $644,936.50. This trade represents a 69.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Dinesh V. Ph D. Patel sold 4,068 shares of Protagonist Therapeutics stock in a transaction that occurred on Tuesday, January 27th. The stock was sold at an average price of $83.19, for a total value of $338,416.92. Following the transaction, the chief executive officer owned 574,505 shares of the company’s stock, valued at $47,793,070.95. This represents a 0.70% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 203,167 shares of company stock worth $16,889,199 in the last three months. Insiders own 4.90% of the company’s stock.

Institutional Investors Weigh In On Protagonist Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Greenline Wealth Management LLC bought a new position in Protagonist Therapeutics during the fourth quarter worth $27,000. Osaic Holdings Inc. lifted its stake in shares of Protagonist Therapeutics by 79.5% during the 2nd quarter. Osaic Holdings Inc. now owns 1,185 shares of the company’s stock worth $65,000 after buying an additional 525 shares during the last quarter. Quadrant Capital Group LLC acquired a new stake in shares of Protagonist Therapeutics during the 3rd quarter worth about $90,000. Truvestments Capital LLC boosted its holdings in shares of Protagonist Therapeutics by 60.8% during the 4th quarter. Truvestments Capital LLC now owns 1,161 shares of the company’s stock worth $101,000 after buying an additional 439 shares during the period. Finally, Smartleaf Asset Management LLC boosted its holdings in shares of Protagonist Therapeutics by 23.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,727 shares of the company’s stock worth $151,000 after buying an additional 324 shares during the period. Institutional investors and hedge funds own 98.63% of the company’s stock.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.